References
-
Alastalo, T.P., Li, M., Perez Vde, J., Pham, D., Sawada, H., Wang, J.K., Koskenvuo, M., Wang, L., Freeman, B.A., Chang, H.Y., et al. (2011). Disruption of
$PPAR\gamma$ /$\beta$ -catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival. J. Clin. Invest. 121, 3735-3746. https://doi.org/10.1172/JCI43382 - Ashley, E.A., Powers, J., Chen, M., Kundu, R., Finsterbach, T., Caffarelli, A., Deng, A., Eichhorn, J., Mahajan, R., Agrawal, R., et al. (2005). The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc. Res. 65, 73-82. https://doi.org/10.1016/j.cardiores.2004.08.018
- Barst, R.J. (2005). PDGF signaling in pulmonary arterial hypertension. J. Clin. Invest. 115, 2691-2694. https://doi.org/10.1172/JCI26593
- Benisty, J.I., McLaughlin, V.V., Landzberg, M.J., Rich, J.D., Newburger, J.W., Rich, S., and Folkman, J. (2004). Elevated basic fibroblast growth factor levels in patients with pulmonary arterial hypertension. Chest 126, 1255-1261. https://doi.org/10.1378/chest.126.4.1255
- Brock, M., Samillan, V.J., Trenkmann, M., Schwarzwald, C., Ulrich, S., Gay, R.E., Gassmann, M., Ostergaard, L., Gay, S., Speich, R., et al. (2012). AntagomiR directed against miR-20a restores functional BMPR2 signalling and prevents vascular remodelling in hypoxia-induced pulmonary hypertension. Eur. Heart J. doi:10.1093/eurheartj/ehs060.
- Budhiraja, R., Tuder, R.M., and Hassoun, P.M. (2004). Endothelial dysfunction in pulmonary hypertension. Circulation 109, 159-165. https://doi.org/10.1161/01.CIR.0000102381.57477.50
- Chandra, S.M., Razavi, H., Kim, J., Agrawal, R., Kundu, R.K., de Jesus Perez, V., Zamanian, R.T., Quertermous, T., and Chun, H.J. (2011). Disruption of the apelin-APJ system worsens hypoxia-induced pulmonary hypertension. Arterioscler. Thromb. Vasc. Biol. 31, 814-820. https://doi.org/10.1161/ATVBAHA.110.219980
- Chen, M.M., Ashley, E.A., Deng, D.X., Tsalenko, A., Deng, A., Tabibiazar, R., Ben-Dor, A., Fenster, B., Yang, E., King, J.Y., et al. (2003). Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation 108, 1432-1439. https://doi.org/10.1161/01.CIR.0000091235.94914.75
- Cheng, X., Cheng, X.S., and Pang, C.C. (2003). Venous dilator effect of apelin, an endogenous peptide ligand for the orphan APJ receptor, in conscious rats. Eur. J. Pharmacol. 470, 171-175. https://doi.org/10.1016/S0014-2999(03)01821-1
- Chun, H.J., Ali, Z.A., Kojima, Y., Kundu, R.K., Sheikh, A.Y., Agrawal, R., Zheng, L., Leeper, N.J., Pearl, N.E., Patterson, A.J., et al. (2008). Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J. Clin. Invest. 118, 3343-3354.
- De Mota, N., Reaux-Le Goazigo, A., El Messari, S., Chartrel, N., Roesch, D., Dujardin, C., Kordon, C., Vaudry, H., Moos, F., and Llorens-Cortes, C. (2004). Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release. Proc. Natl. Acad. Sci. USA 101, 10464-10469. https://doi.org/10.1073/pnas.0403518101
- Deng, Z., Morse, J.H., Slager, S.L., Cuervo, N., Moore, K.J., Venetos, G., Kalachikov, S., Cayanis, E., Fischer, S.G., Barst, R.J., et al. (2000). Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am. J. Hum. Genet. 67, 737-744. https://doi.org/10.1086/303059
- Falcao-Pires, I., Goncalves, N., Henriques-Coelho, T., Moreira-Goncalves, D., Roncon-Albuquerque, R. Jr., and Leite-Moreira, A.F. (2009). Apelin decreases myocardial injury and improves right ventricular function in monocrotaline-induced pulmonary hypertension. Am. J. Physiol. Heart Circ. Physiol. 296, H2007-H2014. https://doi.org/10.1152/ajpheart.00089.2009
- Ghofrani, H.A., Morrell, N.W., Hoeper, M.M., Olschewski, H., Peacock, A.J., Barst, R.J., Shapiro, S., Golpon, H., Toshner, M., Grimminger, F., et al. (2010). Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am. J. Respir. Crit. Care Med. 182, 1171-1177. https://doi.org/10.1164/rccm.201001-0123OC
- Giaid, A., and Saleh, D. (1995). Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 333, 214-221. https://doi.org/10.1056/NEJM199507273330403
- Goetze, J.P., Rehfeld, J.F., Carlsen, J., Videbaek, R., Andersen, C. B., Boesgaard, S., and Friis-Hansen, L. (2006). Apelin: a new plasma marker of cardiopulmonary disease. Regul. Pept. 133, 134-138. https://doi.org/10.1016/j.regpep.2005.09.032
- Hamid, R., Cogan, J.D., Hedges, L.K., Austin, E., Phillips, J.A. 3rd, Newman, J.H., and Loyd, J.E. (2009). Penetrance of pulmonary arterial hypertension is modulated by the expression of normal BMPR2 allele. Hum. Mutat. 30, 649-654. https://doi.org/10.1002/humu.20922
- Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell 100, 57-70. https://doi.org/10.1016/S0092-8674(00)81683-9
- Hansmann, G., Wagner, R.A., Schellong, S., Perez, V.A., Urashima, T., Wang, L., Sheikh, A.Y., Suen, R.S., Stewart, D.J., and Rabinovitch, M. (2007). Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferatoractivated receptor-gamma activation. Circulation 115, 1275-1284.
- Hosoya, M., Kawamata, Y., Fukusumi, S., Fujii, R., Habata, Y., Hinuma, S., Kitada, C., Honda, S., Kurokawa, T., Onda, H., et al. (2000). Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin. J. Biol. Chem. 275, 21061-21067. https://doi.org/10.1074/jbc.M908417199
- Humbert, M., Sitbon, O., Chaouat, A., Bertocchi, M., Habib, G., Gressin, V., Yaici, A., Weitzenblum, E., Cordier, J.F., Chabot, F., et al. (2010). Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 122, 156-163. https://doi.org/10.1161/CIRCULATIONAHA.109.911818
- Ishida, J., Hashimoto, T., Hashimoto, Y., Nishiwaki, S., Iguchi, T., Harada, S., Sugaya, T., Matsuzaki, H., Yamamoto, R., Shiota, N., et al. (2004). Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J. Biol. Chem. 279, 26274-26279. https://doi.org/10.1074/jbc.M404149200
- Iwanaga, Y., Kihara, Y., Takenaka, H., and Kita, T. (2006). Downregulation of cardiac apelin system in hypertrophied and failing hearts: Possible role of angiotensin II-angiotensin type 1 receptor system. J. Mol. Cell Cardiol. 41, 798-806. https://doi.org/10.1016/j.yjmcc.2006.07.004
- Izikki, M., Guignabert, C., Fadel, E., Humbert, M., Tu, L., Zadigue, P., Dartevelle, P., Simonneau, G., Adnot, S., Maitre, B., et al. (2009). Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. J. Clin. Invest. 119, 512-523. https://doi.org/10.1172/JCI35070
- Kaneko, F.T., Arroliga, A.C., Dweik, R.A., Comhair, S.A., Laskowski, D., Oppedisano, R., Thomassen, M.J., and Erzurum, S.C. (1998). Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension. Am. J. Respir. Crit. Care Med. 158, 917-923. https://doi.org/10.1164/ajrccm.158.3.9802066
- Kang, Y., Kim, J., Anderson, J.P., Wu, J., Gleim, S.R., Kundu, R.K., McLean, D.L., Kim, J.D., Park, H., Jin, S.W., et al. (2013). Apelin-APJ signaling is a critical regulator of endothelial MEF2 activation in cardiovascular development. Circ. Res. 113, 22-31. https://doi.org/10.1161/CIRCRESAHA.113.301324
- Kawamata, Y., Habata, Y., Fukusumi, S., Hosoya, M., Fujii, R., Hinuma, S., Nishizawa, N., Kitada, C., Onda, H., Nishimura, O., et al. (2001). Molecular properties of apelin: tissue distribution and receptor binding. Biochim. Biophys. Acta 1538, 162-171. https://doi.org/10.1016/S0167-4889(00)00143-9
- Kim, V.N. (2005). Small RNAs: classification, biogenesis, and function. Mol. Cells 19, 1-15. https://doi.org/10.1016/j.molcel.2005.05.026
- Kim, Y., and Kim, V.N. (2012). MicroRNA factory: RISC assembly from precursor microRNAs. Mol. Cell 46, 384-386. https://doi.org/10.1016/j.molcel.2012.05.012
- Kim, J., Kang, Y., Kojima, Y., Lighthouse, J.K., Hu, X., Aldred, M.A., McLean, D.L., Park, H., Comhair, S.A., Greif, D.M., et al. (2013). An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension. Nat. Med. 19, 74-82. https://doi.org/10.1038/nm.3040
- Lee, D.K., Cheng, R., Nguyen, T., Fan, T., Kariyawasam, A.P., Liu, Y., Osmond, D.H., George, S.R., and O'Dowd, B.F. (2000). Characterization of apelin, the ligand for the APJ receptor. J. Neurochem. 74, 34-41.
- Lin, Z., Kumar, A., SenBanerjee, S., Staniszewski, K., Parmar, K., Vaughan, D.E., Gimbrone, M.A. Jr., Balasubramanian, V., Garcia-Cardena, G., and Jain, M.K. (2005). Kruppel-like factor 2 (KLF2) regulates endothelial thrombotic function. Circ. Res. 96, e48-e57. https://doi.org/10.1161/01.RES.0000159707.05637.a1
- Machado, R.D., Eickelberg, O., Elliott, C.G., Geraci, M.W., Hanaoka, M., Loyd, J.E., Newman, J.H., Phillips, J.A. 3rd., Soubrier, F., Trembath, R.C., et al. (2009). Genetics and genomics of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 54, S32-S42. https://doi.org/10.1016/j.jacc.2009.04.015
- Masri, F.A., Xu, W., Comhair, S.A., Asosingh, K., Koo, M., Vasanji, A., Drazba, J., Anand-Apte, B., and Erzurum, S.C. (2007). Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension. Am. J. Physiol. Lung Cell Mol. Physiol. 293, L548-L554. https://doi.org/10.1152/ajplung.00428.2006
- McLaughlin, V.V., and McGoon, M.D. (2006). Pulmonary arterial hypertension. Circulation 114, 1417-1431. https://doi.org/10.1161/CIRCULATIONAHA.104.503540
- McLean, D.L., Kim, J., Kang, Y., Shi, H., Atkins, G.B., Jain, M.K., and Chun, H.J. (2012). Apelin/APJ signaling is a critical regulator of statin effects in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 32, 2640-2643. https://doi.org/10.1161/ATVBAHA.112.300317
- Medhurst, A.D., Jennings, C.A., Robbins, M.J., Davis, R.P., Ellis, C., Winborn, K.Y., Lawrie, K.W., Hervieu, G., Riley, G., Bolaky, J.E., et al. (2003). Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. J. Neurochem. 84, 1162-1172. https://doi.org/10.1046/j.1471-4159.2003.01587.x
- Moncada, S., and Higgs, E.A. (2006). The discovery of nitric oxide and its role in vascular biology. Br. J. Pharmacol. 147 Suppl 1, S193-S201.
- O'Carroll, A.M., Lolait, S.J., and Howell, G.M. (2006). Transcriptional regulation of the rat apelin receptor gene: promoter cloning and identification of an Sp1 site necessary for promoter activity. J. Mol. Endocrinol. 36, 221-235. https://doi.org/10.1677/jme.1.01927
- O'Dowd, B.F., Heiber, M., Chan, A., Heng, H.H., Tsui, L.C., Kennedy, J.L., Shi, X., Petronis, A., George, S.R., and Nguyen, T. (1993). A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 136, 355-360. https://doi.org/10.1016/0378-1119(93)90495-O
- Ozkan, M., Dweik, R.A., Laskowski, D., Arroliga, A.C., and Erzurum, S.C. (2001). High levels of nitric oxide in individuals with pulmonary hypertension receiving epoprostenol therapy. Lung 179, 233-243. https://doi.org/10.1007/s004080000064
- Parikh, V.N., Jin, R.C., Rabello, S., Gulbahce, N., White, K., Hale, A., Cottrill, K.A., Shaik, R.S., Waxman, A.B., Zhang, Y.Y., et al. (2012). MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach. Circulation 125, 1520-1532. https://doi.org/10.1161/CIRCULATIONAHA.111.060269
- Pullamsetti, S.S., Doebele, C., Fischer, A., Savai, R., Kojonazarov, B., Dahal, B.K., Ghofrani, H.A., Weissmann, N., Grimminger, F., Bonauer, A., et al. (2012). Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension. Am. J. Respir. Crit. Care Med. 185, 409-419. https://doi.org/10.1164/rccm.201106-1093OC
- Rabinovitch, M. (2007). Pathobiology of pulmonary hypertension. Annu. Rev. Pathol. 2, 369-399. https://doi.org/10.1146/annurev.pathol.2.010506.092033
- Rai, P.R., Cool, C.D., King, J.A., Stevens, T., Burns, N., Winn, R.A., Kasper, M., and Voelkel, N.F. (2008). The cancer paradigm of severe pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 178, 558-564. https://doi.org/10.1164/rccm.200709-1369PP
- Raja, S.G. (2010). Endothelin receptor antagonists for pulmonary arterial hypertension: an overview. Cardiovasc. Ther. 28, e65-e71. https://doi.org/10.1111/j.1755-5922.2010.00158.x
- Roberts, K.E., McElroy, J.J., Wong, W.P., Yen, E., Widlitz, A., Barst, R.J., Knowles, J.A., and Morse, J.H. (2004). BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease. Eur. Respir. J. 24, 371-374. https://doi.org/10.1183/09031936.04.00018604
- Rubin, L.J. (1997). Primary pulmonary hypertension. N. Engl. J. Med. 336, 111-117. https://doi.org/10.1056/NEJM199701093360207
- Sakao, S., Tatsumi, K., and Voelkel, N.F. (2010). Reversible or irreversible remodeling in pulmonary arterial hypertension. Am. J. Respir. Cell Mol. Biol. 43, 629-634. https://doi.org/10.1165/rcmb.2009-0389TR
- Sen-Banerjee, S., Mir, S., Lin, Z., Hamik, A., Atkins, G.B., Das, H., Banerjee, P., Kumar, A., and Jain, M.K. (2005). Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells. Circulation 112, 720-726. https://doi.org/10.1161/CIRCULATIONAHA.104.525774
- Sheikh, A.Y., Chun, H.J., Glassford, A.J., Kundu, R.K., Kutschka, I., Ardigo, D., Hendry, S.L., Wagner, R.A., Chen, M.M., Ali, Z.A., et al. (2008). In vivo genetic profiling and cellular localization of apelin reveals a hypoxia-sensitive, endothelial-centered pathway activated in ischemic heart failure. Am. J. Physiol. Heart Circ. Physiol. 294, H88-H98. https://doi.org/10.1152/ajpheart.00935.2007
- Simonneau, G., Robbins, I.M., Beghetti, M., Channick, R.N., Delcroix, M., Denton, C.P., Elliott, C.G., Gaine, S.P., Gladwin, M.T., Jing, Z.C., et al. (2009). Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 54, S43-S54. https://doi.org/10.1016/j.jacc.2009.04.012
- Szokodi, I., Tavi, P., Foldes, G., Voutilainen-Myllyla, S., Ilves, M., Tokola, H., Pikkarainen, S., Piuhola, J., Rysa, J., Toth, M., et al. (2002). Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ. Res. 91, 434-440. https://doi.org/10.1161/01.RES.0000033522.37861.69
- Tatemoto, K., Hosoya, M., Habata, Y., Fujii, R., Kakegawa, T., Zou, M.X., Kawamata, Y., Fukusumi, S., Hinuma, S., Kitada, C., et al. (1998). Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem. Biophys. Res. Commun. 251, 471-476. https://doi.org/10.1006/bbrc.1998.9489
- Tatemoto, K., Takayama, K., Zou, M.X., Kumaki, I., Zhang, W., Kumano, K., and Fujimiya, M. (2001). The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul. Pept. 99, 87-92. https://doi.org/10.1016/S0167-0115(01)00236-1
- Tuder, R.M., Groves, B., Badesch, D.B., and Voelkel, N.F. (1994). Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am. J. Pathol. 144, 275-285.
- Tuder, R.M., Cool, C.D., Yeager, M., Taraseviciene-Stewart, L., Bull, T.M., and Voelkel, N.F. (2001). The pathobiology of pulmonary hypertension. Endothelium Clin. Chest Med. 22, 405-418. https://doi.org/10.1016/S0272-5231(05)70280-X
- Urbich, C., Kuehbacher, A., and Dimmeler, S. (2008). Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc. Res. 79, 581-588. https://doi.org/10.1093/cvr/cvn156
- Zaidi, S.H., You, X.M., Ciura, S., Husain, M., and Rabinovitch, M. (2002). Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension. Circulation 105, 516-521. https://doi.org/10.1161/hc0402.102866
- Zamanian, R.T., Hansmann, G., Snook, S., Lilienfeld, D., Rappaport, K.M., Reaven, G.M., Rabinovitch, M., and Doyle, R.L. (2009). Insulin resistance in pulmonary arterial hypertension. Eur. Respir. J. 33, 318-324.
Cited by
- Negative regulation of NOD1 mediated angiogenesis by PPARγ-regulated miR-125a vol.482, pp.1, 2017, https://doi.org/10.1016/j.bbrc.2016.11.032
- A PPARγ-dependent miR-424/503-CD40 axis regulates inflammation mediated angiogenesis vol.7, pp.1, 2017, https://doi.org/10.1038/s41598-017-02852-4
- Advances in treatment of pulmonary arterial hypertension: patent review vol.27, pp.8, 2017, https://doi.org/10.1080/13543776.2017.1313232
- MicroRNAs in pulmonary arterial hypertension: pathogenesis, diagnosis and treatment vol.9, pp.3, 2015, https://doi.org/10.1016/j.jash.2014.12.011
- Update in treatment options in pulmonary hypertension vol.35, pp.6, 2016, https://doi.org/10.1016/j.healun.2016.01.020
- Microglia-Induced Maladaptive Plasticity Can Be Modulated by NeuropeptidesIn Vivo vol.2015, 2015, https://doi.org/10.1155/2015/135342
- Epigenetic modulation as a therapeutic approach for pulmonary arterial hypertension vol.47, pp.7, 2015, https://doi.org/10.1038/emm.2015.45
- Reversal of MicroRNA Dysregulation in an Animal Model of Pulmonary Hypertension vol.11, pp.1, 2016, https://doi.org/10.1371/journal.pone.0147827
- New targets for pulmonary arterial hypertension vol.23, pp.5, 2017, https://doi.org/10.1097/MCP.0000000000000404
- Scutellarin attenuates vasospasm through the Erk5-KLF2-eNOS pathway after subarachnoid hemorrhage in rats vol.34, 2016, https://doi.org/10.1016/j.jocn.2016.09.028
- Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension vol.130, pp.24, 2014, https://doi.org/10.1161/CIRCULATIONAHA.114.006974
- Endothelial miR-26a regulates VEGF-Nogo-B receptor-mediated angiogenesis vol.50, pp.7, 2017, https://doi.org/10.5483/BMBRep.2017.50.7.085
- Emerging role of angiogenesis in adaptive and maladaptive right ventricular remodeling in pulmonary hypertension vol.314, pp.3, 2018, https://doi.org/10.1152/ajplung.00374.2017
- Epigenetic Regulation and Its Therapeutic Potential in Pulmonary Hypertension vol.9, pp.1663-9812, 2018, https://doi.org/10.3389/fphar.2018.00241
- GPCRs in pulmonary arterial hypertension: tipping the balance vol.175, pp.15, 2018, https://doi.org/10.1111/bph.14172
- Targeting drugs to APJ receptor: From signaling to pathophysiological effects vol.234, pp.1, 2018, https://doi.org/10.1002/jcp.27047
- Acute inhalation of ozone induces DNA methylation of apelin in lungs of Long-Evans rats vol.30, pp.4-5, 2018, https://doi.org/10.1080/08958378.2018.1483984
- Emerging therapeutics in pulmonary hypertension vol.314, pp.5, 2018, https://doi.org/10.1152/ajplung.00259.2017
- The Search for Disease-Modifying Therapies in Pulmonary Hypertension pp.1940-4034, 2019, https://doi.org/10.1177/1074248419829172
- Therapeutic implications of microRNAs in pulmonary arterial hypertension vol.47, pp.6, 2014, https://doi.org/10.5483/bmbrep.2014.47.6.085
- LncRNA H19 promotes the proliferation of pulmonary artery smooth muscle cells through AT 1 R via sponging let-7b in monocrotaline-induced pulmonary arterial hypertension vol.19, pp.None, 2014, https://doi.org/10.1186/s12931-018-0956-z
- The Role of G Protein-Coupled Receptors in the Right Ventricle in Pulmonary Hypertension vol.5, pp.None, 2014, https://doi.org/10.3389/fcvm.2018.00179
- A Systematic Exploration of Macrocyclization in Apelin-13: Impact on Binding, Signaling, Stability, and Cardiovascular Effects vol.61, pp.6, 2014, https://doi.org/10.1021/acs.jmedchem.7b01353
- International Union of Basic and Clinical Pharmacology. CVII. Structure and Pharmacology of the Apelin Receptor with a Recommendation that Elabela/Toddler Is a Second Endogenous Peptide Ligand vol.71, pp.4, 2014, https://doi.org/10.1124/pr.119.017533
- The apelinergic system: a perspective on challenges and opportunities in cardiovascular and metabolic disorders vol.1455, pp.1, 2019, https://doi.org/10.1111/nyas.14123
- Current Treatment Strategies and Nanoparticle-Mediated Drug Delivery Systems for Pulmonary Arterial Hypertension vol.20, pp.23, 2014, https://doi.org/10.3390/ijms20235885
- Apelin+ Endothelial Niche Cells Control Hematopoiesis and Mediate Vascular Regeneration after Myeloablative Injury vol.25, pp.6, 2014, https://doi.org/10.1016/j.stem.2019.10.006
- Elabela: A Novel Biomarker for Right Ventricular Pressure Overload in Children With Pulmonary Stenosis or Pulmonary Atresia With Intact Ventricular Septum vol.7, pp.None, 2014, https://doi.org/10.3389/fcvm.2020.581848
- Activation of the IL-1β/KLF2/HSPH1 pathway promotes STAT3 phosphorylation in alveolar macrophages during LPS-induced acute lung injury vol.40, pp.3, 2014, https://doi.org/10.1042/bsr20193572
- Targeted Drugs for Treatment of Pulmonary Arterial Hypertension: Past, Present, and Future Perspectives vol.63, pp.24, 2014, https://doi.org/10.1021/acs.jmedchem.0c01093
- Current and future treatments of pulmonary arterial hypertension vol.178, pp.1, 2021, https://doi.org/10.1111/bph.15016
- Apelin pathway in cardiovascular, kidney, and metabolic diseases: Therapeutic role of apelin analogs and apelin receptor agonists vol.147, pp.None, 2014, https://doi.org/10.1016/j.peptides.2021.170697